SCLC, small-cell lung carcinoma
Utility of five commonly used immunohistochemical markers TTF-1, Napsin A, CK7, CK5/6 and P63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: a retrospective study of 246 fine needle aspiration cases
... Primary lung carcinomas have been classified into small cell lung carcinoma (SCLC) and non-small cell lung carcinoma ...adeno- carcinoma ...
13
Studying combined effects of chemotherapy and radiotherapy on blood cell counts in lung cancer patients
... of lung cancer; small cell lung carcinoma (SCLC) and non-small cell lung carcinoma ...of SCLC is due to cigarette ...some lung cancers. ...
8
<p>Lambert-Eaton Myasthenic syndrome: early diagnosis is key</p>
... Abstract: Lambert-Eaton myasthenic syndrome (LEMS) is an uncommon disorder of neuromuscular transmission with distinctive pathophysiological, clinical, electrophysiologi- cal and laboratory features. There are two forms ...
11
Relapse of both small cell lung cancer and Lambert–Eaton myasthenic syndrome after a 13-year disease-free survival period
... of small cell lung carcinoma (SCLC) patients have ...of SCLC after a disease-free survival (DFS) of more than 10 years is ...both SCLC and LEMS after a 13-year DFS ...and ...
5
Gastrin releasing peptide is a selective mitogen for small cell lung carcinoma in vitro
... in SCLC cells. Among four lung cancer cell lines examined in vitro, GRP exhibited mitogenic activity for two SCLC subtypes, but not for a squamous carcinoma or adenocarcinoma ...
5
A Brief Review on Lung Cancer
... 2016 Lung cancer is one of the most leading causes of cancer death in the ...world. Lung cancer, also known as lung carcinoma, is a malignant lung tumor characterized by uncontrolled ...
8
Original Article Prognostic value of neuroendocrine markers for predicting survival in patients with small cell lung cancer
... with small cell lung carcinoma (SCLC) present neuroendocrine (NE) properties and chromogranin A (CGA), synaptophysin (Syn), and neural cell adhesion molecule 1 (NCAM1) are known ...
10
An immunohistochemical study of cyclin dependent kinase 5 (CDK5) expression in non small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker
... 365 lung cancers and 30 normal lung ...total lung material was mounted into three blocks. The age range of lung can- cer patients was from 19 to 84 years and was from 19 to 73 years of normal ...
8
Langerhans dendritic cells, tobacco smoke and lung tumours
... SCC squamous cell carcinoma SCLC small cell lung cancer T A A tumour associated antigen TGF transforming growth factor TIL tumour infiltrating lymphocytes TNCB 2,4,6-trinitrochorobenzene[r] ...
247
Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation
... non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC) is a well-recognized mechanism of resistance in EGFR-mutant adeno- carcinoma upon treatment with ...
6
MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs
... of lung cancer, several studies have attempted to distinguish the miRNA profiles of histological subtypes showing the potential of miRNA profiles as diagnostic markers for distinguishing specific subtypes, such as ...
12
Pathological transition as the arising mechanism for drug resistance in lung cancer
... SCLC: small cell lung cancer; NSCLC: non-small cell lung cancer; ADC: adenocarcinoma; SCC: squamous cell carcinoma; LCC: large cell carcinoma; ...
13
Gender Related Survival in Different Stages of Lung Cancer—A Population Study over 20 Years
... The reason for the better survival in females with early stages of NSCLC could be a higher frequency of more highly differentiated adenocarcinomas with low proliferation indexes as reported by Sterlacci et al. [21]. ...
13
Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase
... According to well-known “Warburg effect” characterized by increased glycolysis and lactate production regardless of oxygen availability in malignant tumor cells compared with adjacent normal cells, the tumor cells with ...
16
Drug resistance in lung cancer
... Resistance to another small molecule inhibitor reported is against the angiogenesis inhibitor bevacizumab. Angiogenesis is the growth of new blood vessels from preexisting blood vessels. As we know, tumor cells ...
14
ZAR1 is a novel epigenetically inactivated tumour suppressor in lung cancer
... human lung, but relatively lowered in other tested ...in lung cancer cell ...in lung cancer cell lines but also in pri- mary lung cancer of the SCLC and NSCLC ...in ...
12
Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo
... the release of two cytokines ENA-78 and Gro-alpha which are involved in inflammation and angiogenesis [22]. ENA-78 has been shown to be elevated in NSCLC surgical samples and correlates with tumor growth and vascularity ...
11
An adherent subline of a unique small cell lung cancer cell line downregulates antigens of the neural cell adhesion molecule
... neural cell adhesion molecule (NCAM) on SCLC ...adherent SCLC-v lines were also found to be unreactive with UJ13A and HNK-1, generalizing the association between NCAM expression and the growth of ...
8
Endoplasmic reticulum Ca2+-homeostasis is altered in small and non-small cell lung cancer cell lines
... believe small cell lung carcino- mas to origin from neuro-epithelial ...large cell carcinomas and adeno carcinomas is less ...malignant cell lines with, we decided to use normal human ...
7
Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide
... stage SCLC were treated with up to six cycles of carboplatin and etoposide chemotherapy every 3 weeks, and randomly assigned to receive either oral thalidomide or matching placebo for up to 2 years (LLCG study 12, ...
7